**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 18482**

**Manuscript Type: Topic Highlights**

**2015 Advances in Colorectal Cancer**

**Transanal total mesorectal excision: a valid option for rectal cancer?**

Buchs NC *et al*. Transanal TME

Nicolas C Buchs**,** Gary A Nicholson, Frederic Ris, Neil J Mortensen, Roel Hompes

**Nicolas C Buchs, Gary A Nicholson, Neil J Mortensen, Roel Hompes,** Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospitals, Oxford

OX3 7LE, United Kingdom

**Nicolas C Buchs, Frederic Ris,** Division of Visceral Surgery, Department of Surgery, University Hospitals of Geneva, Geneva 1211, Switzerland

**Gary A Nicholson, Neil J Mortensen,** Nuffield Department of Surgical Science, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom

**Author contributions:** Buchs N and Hompes R designed the research; Buchs N, Hompes R, and Nicholson G performed the research (acquisition of data); Buchs N, Hompes R, Mortensen N and Ris F analyzed and interpreted the data; Buchs N, Hompes R and Nicholson G wrote the article; Mortensen N, Nicholson G and Ris F revised the article; all authors gave their final approval.

**Conflict-of-interest statement:** Roel Hompes is a regular faculty member for TAMIS courses organized by Applied Medical.The other authors have no financial disclosure or conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Nicolas C Buchs, MD,** Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospitals, Old Road, OX3 7LE, Oxford, United Kingdom. nicolas.c.buchs@hcuge.ch

**Telephone:** +44-18-65741841

**Fax:** +44-18-65235857

**Received:** April 21, 2015

**Peer-review started:** April 22, 2015

**First decision:** July 13, 2015

**Revised:** July 21, 2015

**Accepted:** September 13, 2015

**Article in press:**

**Published online:**

**Abstract**

Low Anterior Resection can be a challenging operation, especially in obese male patients and in particular after radiotherapy. Transanal total mesorectal excision (TaTME) might offer technical advantages over laparoscopic or open approaches particularly for tumors in the distal third of the rectum. The aim of this article is to review the current experience with TaTME. The limits and future developments are also explored. Although the experience with TaTME is still limited, it might be a promising alternative to laparoscopic TME, especially for difficult cases where laparoscopy is too demanding. The preliminary data on complications and short-term oncological outcomes are good, but also emphasize the importance of careful patient selection. Finally, there is a need for large-scale trials focusing on long-term outcomes and oncological safety before widespread adoption can be recommended.

**Keys words:** Transanal; Total mesorectal excision; bottom up; Transanal minimally invasive surgery; Laparoscopy; Robotic; Outcomes; Rectal cancer

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The current literature regarding transanal total mesorectal excision of the rectum (TaTME) is presented. Outcomes are encouraging. TaTME might be a promising alternative to laparoscopic TME, especially for difficult cases where laparoscopy is too demanding. The limitations and future developments are explored.

Buchs NC**,** Nicholson GA, Ris F, Mortensen NJ, Hompes R. Transanal total mesorectal excision: a valid option for rectal cancer? *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Rectal adenocarcinoma remains one of the most common cancers in developed countries[[1](#_ENREF_1)]. Its surgical management has evolved in parallel over the past century from open to minimally invasive surgery, then from local resection to total mesorectal excision (TME), and from abdominal to transanal approach.

The adoption of TME was a major step towards better oncological outcomes[[2](#_ENREF_2)], as were more precise definitions of distal and circumferential resection margins (CRM) and minimum number of harvested lymph nodes[[3](#_ENREF_3)]. Indeed, achieving a good quality of surgery is of paramount importance for rectal resection[[4](#_ENREF_4)]. The interest to develop better surgical techniques has therefore been continuously growing.

Whilst the safety of laparoscopy has been established in several randomized studies[[5-8](#_ENREF_5)], Low Anterior Resection (LAR) can be technically challenging, especially in obese male patients, and in particular after chemoradiotherapy due to scarring and distorsion of anatomical planes. The risk of positive margins has been reported to be significant after open or laparoscopic surgery, particularly for low and anterior rectal tumors[[5](#_ENREF_5),[9](#_ENREF_9)].

In addition, in challenging patients, difficulties in pelvic exposure and limitations of instrumentation can affect not only dissection but also the preservation of autonomic pelvic nerves and the achievement of a restorative procedure[[10](#_ENREF_10)]. These unsolved problems have led surgical innovators to explore the concept of laparoscopy for low rectal cancers. Whilst some groups have successfully employed the robotic approach to reduce these risks[[11](#_ENREF_11),[12](#_ENREF_12)], there remains a paucity of data regarding the superiority of robotics regarding the oncological outcomes thus far.

Based on this, the concept of “bottom-up” or transanal total mesorectal excision (TaTME) is attractive. Whilst not novel, TaTME has benefited from the previous experience with TransAbdominal-TransAnal (TATA) operation[[13-15](#_ENREF_13)]. Following the developments of NOTES (Naturally Orifice Transluminal Endoscopic Surgery), TEM (Transanal Endoscopic Microsurgery) and TAMIS (Transanal Minimally Invasive Surgery), TaTME has been reported as feasible and safe in several large studies[[16-23](#_ENREF_16)]. However, the real oncological impact of this technique remains under scrutiny. The aim of this article is to analyse the current experience with TaTME. The limits and future developments are also explored.

**TECHNICAL CONSIDERATIONS**

TaTME has been developed to overcome the inherent limits of standard approaches, either open or laparoscopic. Indeed, a laparoscopic LAR remains particularly challenging, notably regarding exposure, rectal dissection, and distal cross stapling of the rectum. Starting with dissection from the perineum seems to offer advantages, by avoiding distal cross stapling in a narrow pelvis. The use of laparoscopic staplers in this situation is difficult as multiple staple firings across the low rectum increase potential for anastomotic leak[[24](#_ENREF_24)].

As mentioned, the concept to start the dissection from the perineum is not new. Indeed, the TATA approach has proven feasible and safe for many years[[25](#_ENREF_25)]. However, the authors did not use either minimally invasive instruments or a platform for the transanal portion of the TATA procedure. TaTME might therefore have advantages in terms of vision and dissection due to utilisation of CO2 for insufflation. Overall though, the global aims are the same, namely: to increase the sphincter-saving rate, to reduce positive margins, and to avoid low staple firing.

TaTME, like TATA, has the potential to define the radial and distal margins more clearly. This might be ideal in patients for whom a laparoscopic pelvic dissection is difficult (male, obese, preoperative radiotherapy, tumor located in the lower third of the rectum), carrying a risk of inadequate oncological clearance[[19](#_ENREF_19)]. With TaTME, distal margin is assessed precisely from the beginning of the procedure. It therefore has the potential to (1) improve resection quality, and therefore clinical outcomes; and (2) decrease the incidence of abdominoperineal resection (APR), thereby improving sphincter preservation rates[[26](#_ENREF_26)].

From a technical point of view, a transanal purse-string suture below the tumor ensures an adequate oncological distal margin will be achieved[[27](#_ENREF_27)]. This approach has the advantage of providing excellent visualization even in a narrow pelvis. It could facilitate the dissection of the Denonvilliers fascia minimizing injury to the prostate, seminal vesicles, or vagina. This is especially true in anterior tumors, as they have a high risk of positive CRM. It might also afford more precise autonomic nerve preservation[[18](#_ENREF_18)].

Currently, the majority of authors still use abdominal assistance. However, a purely transanal approach is feasible, as reported by several groups[[28-30](#_ENREF_28)]. A recent systematic review found 10% of groups using a purely NOTES approach[[16](#_ENREF_16)]. To illustrate, Chouillard *et al*[[29](#_ENREF_29)] performed 62.5% of their cases without abdominal assistance. However, if splenic flexure mobilization is required, abdominal assistance seems appropriate. It can be performed by single port also[[31](#_ENREF_31)]. The same is true for the creation of a defuntioning ileostomy[[32](#_ENREF_32)], which is better approached laparoscopically than transanally. In cases of abdominal assistance, the TaTME technique allows for working simultaneously both from above and below. The operation is then performed in the lithotomy position utilizing a team approach (either metachronously or synchronously). This can have at least one advantage, namely a shorter operating time[[19](#_ENREF_19)].

The TaTME approach allows for exteriorization of the specimen transanally. However, transanal extraction of the surgical specimen en bloc may not always be possible, particularly in patients with a narrow, deep pelvis, bulky mesentery, and constraints imposed by other pelvic viscera, such as prostatic hypertrophy[[33](#_ENREF_33)]. When possible, transanal extraction avoids large abdominal extraction incisions and their associated potential complications. A wound protector is advised to minimize the risk of tumor spillage.

**INITIAL EXPERIENCE**

The use of minimally invasive instruments and new platforms was inspired by NOTES and TEM/TAMIS. The first experience demonstrated in cadaveric models starting in 2007 by Whiteford *et al*[[34](#_ENREF_34)] was soon followed by others[[35](#_ENREF_35),[36](#_ENREF_36)]. These authors demonstrated the feasibility of the concept, and recognized the critical steps for this procedure. Three years later, the first human clinical case was published[[37](#_ENREF_37)]. Although the case was well selected (a female with low BMI and a mid-rectum tumor), the proof of concept was established, confirmed shortly thereafter by several case reports and small case series[[28](#_ENREF_28),[30](#_ENREF_30),[38](#_ENREF_38)]. More recently, larger series have been published (Table 1)[[17](#_ENREF_17),[18](#_ENREF_18),[20-22](#_ENREF_20),[25](#_ENREF_25),[29](#_ENREF_29),[39-44](#_ENREF_39)], confirming their initial experience.

To illustrate, Tuech *et al*[[22](#_ENREF_22)] recently published a multicentre study, regrouping 56 TaTME patients. They reported very good short-term (Table 1) and pathological outcomes (Table 2). Interestingly, they also reported their oncological outcomes. They found a local recurrence rate of 1.7% at 24 mo. For their entire series, the overall survival rate was 96.4% after a median follow-up of 29 months. The estimated 5-year disease-free survival rate was 94.2%. Similar oncological findings were reported by Muratore *et al*[[20](#_ENREF_20)]. These results compared favorably to large TATA series[[25](#_ENREF_25)].

In another large published series, Rouanet *et al*[[21](#_ENREF_21)] reported encouraging outcomes in difficult patients (male, 54% overweight or obese, 83.3% CRM threatened according to preoperative MRI, 96.7% with neoadjuvant treatment). Despite this challenging and unfavourable population, they showed good peri-operative and pathological outcomes. Of note, two cases of urethral injury were observed at the beginning of the experience, emphasizing the need for a significant learning curve and great caution when performing dissection anteriorly. Finally, the overall survival and disease-free survival rates were 80.5% and 88.9% at 24 mo, in a high-risk population.

When assessing a new surgical technique for rectal cancer, the pathological outcomes are of paramount importance. A good quality TME specimen is essential, as it remains an independent risk factor for local recurrence[[45](#_ENREF_45)]. The majority of authors using TaTME have reported excellent specimen quality and adequate margins (Table 2).

It is quite clear that TaTME, regardless of the specific equipment utilized, the performance of a sequential or synchronous technique, the height of the tumor, or the use of neoadjuvant therapy, seems to influence the ability to achieve a complete or near-complete TME[[4](#_ENREF_4)], as confirmed in recent systematic reviews[[3](#_ENREF_3),[16](#_ENREF_16)].

**COMPARISON TO STANDARD TME**

A logical next step was the comparison to standard approaches. Recently, several studies evaluating TaTME in comparison to laparoscopic TME have been published (Tables 3 and 4).

Lately, Denost *et al*[[46](#_ENREF_46)] published a randomized trial, comparing standard laparoscopic TME with perineal transanal TME for low rectal cancer (< 6 cm from the anal verge). In contrast to other groups, they performed the perineal dissection using traditional instruments rather than laparoscopic instruments. While they recognized that TEM equipment was an option, they did not need special platforms. Although it was not *sensu stricto* a TaTME, this experience confirmed the proof of concept, demonstrating that starting from the perineum has some advantages. They showed that the positive CRM rate was reduced in the perineal group (4% *vs* 18% for standard TME; *p =* 0.025). After multivariate analysis, the abdominal dissection was the only independent factor of positive CRM. Furthermore, the quality of the TME specimen was similar in both groups. In addition, the rate of anastomotic leakage (2% *vs* 10%), the operative time (240 *vs* 263 min) and the conversion rate (4% *vs* 10%) were decreased in the perineal group compared with the abdominal group. These differences did not reach the level of statistical significance.

In a recent case-matched series, Fernandez-Hevia *et al*[[19](#_ENREF_19)] proffered interesting results. They compared 37 laparoscopic TME resections with 37 transanal endoscopic TME resections. Overall they showed better short-term outcomes following TaTME, with a shorter operative time (minus 37 min; *p <* 0.01), a shorter hospital stay (minus 2.2 d; *p =* 0.1), and less readmission (6% *vs* 22% for standard TME; *p =* 0.03). The TaTME group tended to present less complications as well (32% *vs* 51%), although this did not reach statistical significance (*p =* 0.16). Regarding anastomotic leak, there was a trend in favour of TaTME group (5% *vs* 11%; *p =* 0.39). Finally, with the exception of a longer distal margin (overall + 1.1 cm; *p <* 0.01), the transanal group showed similar pathological data.

In further case-matched study, Velthuis *et al*[[23](#_ENREF_23)] focused on pathological outcomes. They showed some advantages for the TaTME approach with 96% of patients having a complete TME specimen, while in the laparoscopic group, only 72% presented an intact specimen (*p <* 0.05). The difference is even more obvious when considering abdominoperineal excision (83% *vs* 33%). There were less positive CRMs in the TaTME group (4% *vs* 8%), although the difference was not statistically significant.

Overall achievement of oncological resection principles is confirmed by an identical number of lymph nodes harvested in both groups and by similar, if not better, R0 rate after TaTME (Table 4). The same is reported for the quality of TME. Better short-term outcomes might also be expected. So far however, the differences have not reached statistical significance. This could be accounted for by small sample sizes. Nonetheless, these results are promising and should motivate further research.

**ROLE OF ROBOTICS**

One feature robotic technology offers the surgeon is a 3-dimensional (3D) view. It is thought that this could provide advantages in terms of more accuracy during dissection. Others have also reported the use of 3D laparoscopic camera with success[[19](#_ENREF_19)]. However, beyond the quality of vision, the interest of robotics is more associated with the manoeuvrability of the instruments and the stability of the platform. After initial successful cadaveric experience[[47](#_ENREF_47)], published data regarding the clinical use of robotics for TaTME are encouraging albeit limited (Table 5)[[48-52](#_ENREF_48)]. Of note, the use of robotic technology in this situation might restrict the possibility to work simultaneously from the abdomen and the perineum (concept of a two-team approach), which might have been a source of time saving. Regarding this experience, the feasibility has been established. Although the number of patients remains limited, the safety seems to be similar as standard TaTME. Real advantages are still hypothetical but robotic technology might help to overcome the steep learning curve, which seems to be associated with TaTME. New single-site surgery platforms are awaited. They may facilitate docking and transanal access[[53](#_ENREF_53)].

**LIMITS AND FUTHER DEVELOPMENTS**

***New technique, new complications?***

When any new surgical technique is adopted, safety is of paramount importance. Whilst an increase in complication rates could be anticipated at the beginning of the learning curve, the global safety has to be guaranteed. However, as it was previously shown for other procedures or technique[[54](#_ENREF_54),[55](#_ENREF_55)], the risk of encountering new or unexpected types of complications is real. Whilst the safety profile of TaTME seems at least similar to the standard approach, the risk of local abscess or collection formation needs to be emphasized. Indeed, Velthuis *et al*[[56](#_ENREF_56)] found a positive pelvic culture in 39% of patients during TaTME. Of these, four (44%) developed presacral abscesses. The remainder of the cultures were negative with none of these patients developing infectious complications. On the other hand, pelvic collection (or anastomotic leak) does not seem to be over-reported in the current literature. Meticulous washout is therefore advocated before and during the procedure, especially before the rectotomy.

One of the most common complications reported was urinary retention and transient urinary dysfunction. Sylla *et al*[[41](#_ENREF_41)] found 2 patients with urinary dysfunction (40% in their pilot study). Urodynamic testing one month postoperatively demonstrated minimal detrusor activity consistent with a neurogenic bladder. These data were confirmed on a smaller scale by Tuech *et al*[[22](#_ENREF_22)]; 5 patients presented transient urinary dysfunction (8.9%). This was corrected at 3 months. On the other hand, in their randomized study, Denost *et al*[[46](#_ENREF_46)] did not find any statistical differences between perineal and abdominal dissection in terms of urological complications (6% *vs* 10%; *p =* 0.715). It is therefore worthwhile mentioning the risk of urethral lesions[[21](#_ENREF_21)] as TaTME may result in an increased incidence of urethral injury, especially at the level of the post-prostatic urethra and particularly in the setting of anterior tumors, and prior pelvic irradiation[[26](#_ENREF_26)]. It is worthwhile mentioning that this complication rarely, if ever, occurs for standard TME.

Finally, pneumopelvis is worthy of mention, as an aid during dissection. Atallah[[26](#_ENREF_26)] has noted that CO2 might also show areolar planes beyond the scope of dissection thus leading the surgeon astray. This could occur in two distinct areas: (1) laterally, at the level of the mid rectum; and (2) posteriorly, at the level of the mid and upper rectum, placing the operating surgeon in a plane that is ‘too deep,’ thereby entering the pre-sacral space. Going off plane can result in inadvertent injury to both pelvic sidewall autonomic nerves and the sacral venous plexus posteriorly, resulting in haemorrhage[[26](#_ENREF_26)].

***Oncological outcomes***

Oncological outcomes for TaTME are scarcely reported. Preliminary data seem encouraging though. Indeed, in one of the largest series of 56 consecutive patients, Tuech *et al*[[22](#_ENREF_22)] found a local recurrence rate of 1.7% at 24 mo. After a median follow-up of 29 months, the overall survival rate was 96.4%. The estimated 5-year disease-free survival rate was 94.2%. These results were substantiated by Muratore *et al*[[20](#_ENREF_20)], showing an overall survival and disease-free rate of 92.3% after a mean follow up of 21 months. In addition, they did not report any local recurrence. Even when assessing high-risk patients, Rouanet *et al*[[21](#_ENREF_21)] found an overall survival and disease-free survival rate of 80.5% and 88.9% at 24 mo respectively.

A word of caution though: the risk of poor outcomes should be mentioned, especially when dealing with locally advanced tumors. In their series, Rouanet *et al*[[21](#_ENREF_21)] have dealt with 23% of patients presenting an initial T4 tumor. In these circumstances, there is a significant risk of worse pathological and oncological outcomes. The most recent studies[[19](#_ENREF_19),[44](#_ENREF_44),[46](#_ENREF_46)] have reported a low rate of preoperative T4 patients. For these challenging patients, it is still not clear which approach is the most appropriate.

Finally, long-term follow-up is required before drawing definitive conclusions regarding the oncological safety of TaTME. Preliminary data are promising though, and at least as good as the standard approach[[8](#_ENREF_8),[57](#_ENREF_57)].

***Functional outcomes***

In tandem with oncological safety, the issue of functional outcomes should be addressed. Poor function can be attributed to a combination of factors: the increased rate of coloanal anastomosis, partial sacrifice of the internal anal sphincter, and the anal stretch during TaTME. To date, functional outcomes have been poorly investigated but TME experience may yield some clues. Indeed, at least one third of the TME patients might present some degree of temporary incontinence[[58](#_ENREF_58)]. On the other hand, the extrapolation of these results to TaTME is hypothetical, especially in a population where the rectum has been removed.

Rouanet *et al*[[21](#_ENREF_21)] showed that at 12 mo after stoma closure, 40% of patients were fully continent, 15% reported incontinence to liquids, 35% to gas, and 25% had stool fragmentation. Atallah *et al*[[17](#_ENREF_17)] confirmed these results and showed that most of the patients had mild fecal incontinence 8 wk after ileostomy closure. Only one patient presented a life-style-limiting incontinence. In their large multicenter study, Tuech *et al*[[22](#_ENREF_22)] found 3 patients (5.7%) requiring definitive colostomy because of severe fecal incontinence after inter-sphincteric resection with coloanal anastomosis. In addition, 28% of their studied group reported stool fragmentation and difficult evacuation.

Finally, in sexually active patients, this French group found 66.6% patients with unchanged ejaculation and 11.2% with failure to ejaculate. Impotence was reported in 11.2% of males[[22](#_ENREF_22)]. These data are in accordance with the standard approach[[59](#_ENREF_59),[60](#_ENREF_60)].

***What next?***

While promising, it is imperative to raise a note of caution: clearly, only high-volume centres with technically adept, minimally invasive surgeons can produce these results[[4](#_ENREF_4)]. There is a need to continue to develop and collaborate in an international registry, collecting relevant and high quality data on transanal rectal resection surgery for benign and malignant pathology. This will allow for safe and responsible introduction of a new technology. It may also be a driver for further research and multicentre studies[[10](#_ENREF_10)]. Recently, the TaTME registry was launched. It is a voluntary database with online access through the LOREC (Low Rectal Cancer Development Program) portal (<http://www.lorec.nhs.uk>)[[10](#_ENREF_10)].

Currently, the main open questions can be categorized as follow: (1) How to overcome the technical limitations? (2) Who are the best candidates (selection criteria)? (3) What are the long-term outcomes (oncological and functional)? (4) How to teach this technique? (5) What are the pre-requisite skills for the surgeon? What is the learning curve? (6) What are the associated costs? and (7) Should everyone be doing it (i.e. is there a minimum case volume)?

From a technical point of view, the current platforms are not ideal and relatively unstable. The introduction of Airseal (SugiQuest) might help to overcome two technical problems: (1) excessive plumes of smoke which obscure the operative field of view; and (2) “bellowing” or collapse and re-expansion of the pelvis with the cycling of CO2[[26](#_ENREF_26)]. The experience with TAMIS was encouraging, allowing maintenance of a stable pneumopelvis[[61](#_ENREF_61)]. However, this technology has a cost and no comparative studies are currently available demonstrating clear objective advantages over standard platforms.

As for laparoscopic LAR, the assessment of CRM is still challenging during TaTME. Developments of intra-operative navigation and augmented reality are both new and interesting fields. Recently, stereotactic navigation has been tested for TaTME[[62](#_ENREF_62)], to ensure R0 resection. This might be particularly relevant for locally advanced tumors. The accuracy was reported to be +/- 4 mm. This technology seems to have potential, especially when applied to pelvic and fixed abdominal organs[[63](#_ENREF_63)], as it was reported for liver surgery[[64](#_ENREF_64),[65](#_ENREF_65)].

A fully NOTES procedure might be the final step. It has already been reported as feasible and safe by others[[28-30](#_ENREF_28)]. The main technical advantage of NOTES is the absence of abdominal scars, conferring a cosmetic benefit. In addition, a reduction in pain and incision-related complications might be expected too. This said, the splenic flexure mobilization and the stoma formation are probably best performed by an abdominal approach.

The question of selection criteria is probably the most crucial and will continue to animate debate. Even in very difficult patients, Rouanet *et al*[[21](#_ENREF_21)] showed comparable results. Although the risk of positive CRM was slightly higher than expected (13.3%), it is worthwhile noting that they are still comparable to previous data (COLOR II study: 9%-22%)[[5](#_ENREF_5),[8](#_ENREF_8)].

According to Atallah, the best suited surgical candidates are those[[33](#_ENREF_33)]: (1) considered difficult to approach from above; and (2) who have a distal rectal tumor, and who are not candidates for local excision.

Several local anatomical and pathological factors may also favour TaTME. These include male gender, locally advanced rectal cancer, tumors in the distal third of rectum, narrow and/or deep pelvis, visceral obesity, prostatic hypertrophy, large tumor diameter, and distorted tissue planes due to neoadjuvant radiotherapy[[33](#_ENREF_33)]. On the other hand, at least at the beginning of the experience, a locally advanced tumor should be avoided.

Of note, this technique can also be utilized for benign disease, particularly at the beginning of the learning curve. Examples include completion proctectomy for ulcerative colitis or complicated rectovaginal fistulae.

As mentioned, long-term (oncological and functional) outcomes are awaited. There remains little information regarding the ileostomy closure rate and the occurrence of late anastomotic strictures[[16](#_ENREF_16)]. In addition, while preliminary experience of TaTME in comparison to standard LAR is promising, data remains scarce. There is still a clear need for an RCT, and more multicenter series. Again, the need for an international registry is reiterating.

There is definitively a learning curve. It may be steep. Whilst extensive experience with TEM/TAMIS and LAR is a prerequisite, there are no data evaluating this learning curve so far. As for robotic surgery[[66](#_ENREF_66)], there is a gap between the will to teach a specific technique and the practical aspects to integrate this new training in the curriculum. Many advocate animal and/or cadaveric training prior to attempting the procedure[[16](#_ENREF_16)]. Dedicated courses need to be developed. Our preliminary experience with hands on cadaver courses has been encouraging, allowing trainees to perform several successful TaTMEs. Finally, mentoring might also form part of the curriculum.

The cost effectiveness of this new technique is unknown. The direct costs might be higher than the standard approach for variety of reasons: a 2-team procedure requires more staff, more equipment, and personnel familiar with (and trained to use) new devices. However, if the short- then long-term outcomes are confirmed to be better after TaTME, the indirect costs could be in favour of TaTME. This assertion currently remains hypothetical requiring larger dedicated studies.

**CONCLUSION**

Although the experience with TaTME remains limited, it presents a promising alternative to laparoscopic TME, especially for difficult cases where laparoscopy is too demanding. The preliminary data on complications and short-term oncological outcomes are good. They also emphasize the importance of careful patient selection. Finally, there is a need for large-scale trials focusing on long-term outcomes and oncological safety, before widespread adoption can be recommended.

**REFERENCES**

1 Cancer Statistics: Colorectal Cancer. Available from: URL: http: //www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Colorectal/#rectum

2 **van Gijn W**, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ; Dutch Colorectal Cancer G. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011; **12**: 575-582 [PMID: 21596621 DOI: 10.1016/S1470-2045(11)70097-3]

3 **Emhoff IA**, Lee GC, Sylla P. Transanal colorectal resection using natural orifice translumenal endoscopic surgery (NOTES). *Dig Endosc* 2014; **26** Suppl 1: 29-42 [PMID: 24033375 DOI: 10.1111/den.12157]

4 **Wexner SD**, Berho M. Transanal total mesorectal excision of rectal carcinoma: evidence to learn and adopt the technique. *Ann Surg* 2015; **261**: 234-236 [PMID: 25565121 DOI: 10.1097/SLA.0000000000000886]

5 **van der Pas MH**, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ; Group COcLoORIS. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol* 2013; **14**: 210-218 [PMID: 23395398 DOI: 10.1016/S1470-2045(13)70016-0]

6 **Ng SS**, Lee JF, Yiu RY, Li JC, Hon SS, Mak TW, Leung WW, Leung KL. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. *Ann Surg* 2014; **259**: 139-147 [PMID: 23598381 DOI: 10.1097/SLA.0b013e31828fe119]

7 **Kang SB**, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. *Lancet Oncol* 2010; **11**: 637-645 [PMID: 20610322 DOI: 10.1016/S1470-2045(10)70131-5]

8 **Bonjer HJ**, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E; Group CIS. A randomized trial of laparoscopic versus open surgery for rectal cancer. *N Engl J Med* 2015; **372**: 1324-1332 [PMID: 25830422 DOI: 10.1056/NEJMoa1414882]

9 **Battersby NJ**, How P, Moran B, Stelzner S, West NP, Branagan G, Strassburg J, Quirke P, Tekkis P, Pedersen BG, Gudgeon M, Heald B, Brown G; MERCURY II Study Group. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. *Ann Surg* 2015; Epub ahead of print [PMID: 25822672 DOI: 10.1097/SLA.0000000000001193]

10 **Hompes R**, Arnold S, Warusavitarne J. Towards the safe introduction of transanal total mesorectal excision: the role of a clinical registry. *Colorectal Dis* 2014; **16**: 498-501 [PMID: 24806149 DOI: 10.1111/codi.12661]

11 **Baik SH**, Ko YT, Kang CM, Lee WJ, Kim NK, Sohn SK, Chi HS, Cho CH. Robotic tumor-specific mesorectal excision of rectal cancer: short-term outcome of a pilot randomized trial. *Surg Endosc* 2008; **22**: 1601-1608 [PMID: 18270772 DOI: 10.1007/s00464-008-9752-z]

12 **Halabi WJ**, Kang CY, Jafari MD, Nguyen VQ, Carmichael JC, Mills S, Stamos MJ, Pigazzi A. Robotic-assisted colorectal surgery in the United States: a nationwide analysis of trends and outcomes. *World J Surg* 2013; **37**: 2782-2790 [PMID: 23564216 DOI: 10.1007/s00268-013-2024-7]

13 **Ramos JR**. Laparoscopic very low anterior resection and coloanal anastomosis using the pull-through technique. *Dis Colon Rectum* 1995; **38**: 1217-1219 [PMID: 7587768]

14 **Watanabe M**, Teramoto T, Hasegawa H, Kitajima M. Laparoscopic ultralow anterior resection combined with per anum intersphincteric rectal dissection for lower rectal cancer. *Dis Colon Rectum* 2000; **43**: S94-S97 [PMID: 11052484]

15 **Marks GJ**, Marks JH, Mohiuddin M, Brady L. Radical Sphincter preservation surgery with coloanal anastomosis following high-dose external irradiation for the very low lying rectal cancer. *Recent Results Cancer Res* 1998; **146**: 161-174 [PMID: 9670259]

16 **Araujo SE**, Crawshaw B, Mendes CR, Delaney CP. Transanal total mesorectal excision: a systematic review of the experimental and clinical evidence. *Tech Coloproctol* 2015; **19**: 69-82 [PMID: 25380741 DOI: 10.1007/s10151-014-1233-x]

17 **Atallah S**, Martin-Perez B, Albert M, deBeche-Adams T, Nassif G, Hunter L, Larach S. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. *Tech Coloproctol* 2014; **18**: 473-480 [PMID: 24272607 DOI: 10.1007/s10151-013-1095-7]

18 **de Lacy AM**, Rattner DW, Adelsdorfer C, Tasende MM, Fernández M, Delgado S, Sylla P, Martínez-Palli G. Transanal natural orifice transluminal endoscopic surgery (NOTES) rectal resection: "down-to-up" total mesorectal excision (TME)--short-term outcomes in the first 20 cases. *Surg Endosc* 2013; **27**: 3165-3172 [PMID: 23519489 DOI: 10.1007/s00464-013-2872-0]

19 **Fernández-Hevia M**, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. *Ann Surg* 2015; **261**: 221-227 [PMID: 25185463 DOI: 10.1097/SLA.0000000000000865]

20 **Muratore A**, Mellano A, Marsanic P, De Simone M. Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results. *Eur J Surg Oncol* 2015; **41**: 478-483 [PMID: 25633642 DOI: 10.1016/j.ejso.2015.01.009]

21 **Rouanet P**, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, Saint-Aubert B, Colombo PE. Transanal endoscopic proctectomy: an innovative procedure for difficult resection of rectal tumors in men with narrow pelvis. *Dis Colon Rectum* 2013; **56**: 408-415 [PMID: 23478607 DOI: 10.1097/DCR.0b013e3182756fa0]

22 **Tuech JJ**, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, Delpero JR, Hanoun L, Michot F. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. *Ann Surg* 2015; **261**: 228-233 [PMID: 25361216 DOI: 10.1097/SLA.0000000000000994]

23 **Velthuis S**, Nieuwenhuis DH, Ruijter TE, Cuesta MA, Bonjer HJ, Sietses C. Transanal versus traditional laparoscopic total mesorectal excision for rectal carcinoma. *Surg Endosc* 2014; **28**: 3494-3499 [PMID: 24972923 DOI: 10.1007/s00464-014-3636-1]

24 **Ito M**, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y, Saito N. Relationship between multiple numbers of stapler firings during rectal division and anastomotic leakage after laparoscopic rectal resection. *Int J Colorectal Dis* 2008; **23**: 703-707 [PMID: 18379795 DOI: 10.1007/s00384-008-0470-8]

25 **Marks J**, Mizrahi B, Dalane S, Nweze I, Marks G. Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3 cm of the rectum after neoadjuvant therapy. *Surg Endosc* 2010; **24**: 2700-2707 [PMID: 20414681 DOI: 10.1007/s00464-010-1028-8]

26 **Atallah S**. Transanal total mesorectal excision: full steam ahead. *Tech Coloproctol* 2015; **19**: 57-61 [PMID: 25560966 DOI: 10.1007/s10151-014-1254-5]

27 **Hompes R**, Guy R, Jones O, Lindsey I, Mortensen N, Cunningham C. Transanal total mesorectal excision with a side-to-end stapled anastomosis - a video vignette. *Colorectal Dis* 2014; **16**: 567 [PMID: 24801986 DOI: 10.1111/codi.12660]

28 **Leroy J**, Barry BD, Melani A, Mutter D, Marescaux J. No-scar transanal total mesorectal excision: the last step to pure NOTES for colorectal surgery. *JAMA Surg* 2013; **148**: 226-30; discussion 231 [PMID: 23682369]

29 **Chouillard E**, Chahine E, Khoury G, Vinson-Bonnet B, Gumbs A, Azoulay D, Abdalla E. NOTES total mesorectal excision (TME) for patients with rectal neoplasia: a preliminary experience. *Surg Endosc* 2014; **28**: 3150-3157 [PMID: 24879139 DOI: 10.1007/s00464-014-3573-z]

30 **Zhang H**, Zhang YS, Jin XW, Li MZ, Fan JS, Yang ZH. Transanal single-port laparoscopic total mesorectal excision in the treatment of rectal cancer. *Tech Coloproctol* 2013; **17**: 117-123 [PMID: 22936590 DOI: 10.1007/s10151-012-0882-x]

31 **Dumont F**, Goéré D, Honoré C, Elias D. Transanal endoscopic total mesorectal excision combined with single-port laparoscopy. *Dis Colon Rectum* 2012; **55**: 996-1001 [PMID: 22874608 DOI: 10.1097/DCR.0b013e318260d3a0]

32 **Atallah S**. Transanal minimally invasive surgery for total mesorectal excision. *Minim Invasive Ther Allied Technol* 2014; **23**: 10-16 [PMID: 23992386 DOI: 10.3109/13645706.2013.833118]

33 **Atallah S**, Albert M, DeBeche-Adams T, Nassif G, Polavarapu H, Larach S. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): a stepwise description of the surgical technique with video demonstration. *Tech Coloproctol* 2013; **17**: 321-325 [PMID: 23377536 DOI: 10.1007/s10151-012-0971-x]

34 **Whiteford MH**, Denk PM, Swanström LL. Feasibility of radical sigmoid colectomy performed as natural orifice translumenal endoscopic surgery (NOTES) using transanal endoscopic microsurgery. *Surg Endosc* 2007; **21**: 1870-1874 [PMID: 17705068 DOI: 10.1007/s00464-007-9552-x]

35 **Telem DA**, Han KS, Kim MC, Ajari I, Sohn DK, Woods K, Kapur V, Sbeih MA, Perretta S, Rattner DW, Sylla P. Transanal rectosigmoid resection via natural orifice translumenal endoscopic surgery (NOTES) with total mesorectal excision in a large human cadaver series. *Surg Endosc* 2013; **27**: 74-80 [PMID: 22752277 DOI: 10.1007/s00464-012-2409-y]

36 **McLemore EC**, Coker AM, Devaraj B, Chakedis J, Maawy A, Inui T, Talamini MA, Horgan S, Peterson MR, Sylla P, Ramamoorthy S. TAMIS-assisted laparoscopic low anterior resection with total mesorectal excision in a cadaveric series. *Surg Endosc* 2013; **27**: 3478-3484 [PMID: 23494511 DOI: 10.1007/s00464-013-2889-4]

37 **Sylla P**, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. *Surg Endosc* 2010; **24**: 1205-1210 [PMID: 20186432 DOI: 10.1007/s00464-010-0965-6]

38 **Tuech JJ**, Bridoux V, Kianifard B, Schwarz L, Tsilividis B, Huet E, Michot F. Natural orifice total mesorectal excision using transanal port and laparoscopic assistance. *Eur J Surg Oncol* 2011; **37**: 334-335 [PMID: 21266304 DOI: 10.1016/j.ejso.2010.12.016]

39 **Han Y**, He YG, Zhang HB, Lv KZ, Zhang YJ, Lin MB, Yin L. Total laparoscopic sigmoid and rectal surgery in combination with transanal endoscopic microsurgery: a preliminary evaluation in China. *Surg Endosc* 2013; **27**: 518-524 [PMID: 22806529 DOI: 10.1007/s00464-012-2471-5]

40 **Knol JJ**, D'Hondt M, Souverijns G, Heald B, Vangertruyden G. Transanal endoscopic total mesorectal excision: technical aspects of approaching the mesorectal plane from below--a preliminary report. *Tech Coloproctol* 2015; **19**: 221-229 [PMID: 25702172 DOI: 10.1007/s10151-015-1275-8]

41 **Sylla P**, Bordeianou LG, Berger D, Han KS, Lauwers GY, Sahani DV, Sbeih MA, Lacy AM, Rattner DW. A pilot study of natural orifice transanal endoscopic total mesorectal excision with laparoscopic assistance for rectal cancer. *Surg Endosc* 2013; **27**: 3396-3405 [PMID: 23572214 DOI: 10.1007/s00464-013-2922-7]

42 **Velthuis S**, van den Boezem PB, van der Peet DL, Cuesta MA, Sietses C. Feasibility study of transanal total mesorectal excision. *Br J Surg* 2013; **100**: 828-31; discussion 831 [PMID: 23440708 DOI: 10.1002/bjs.9069]

43 **Wolthuis AM**, de Buck van Overstraeten A, D'Hoore A. Dynamic article: transanal rectal excision: a pilot study. *Dis Colon Rectum* 2014; **57**: 105-109 [PMID: 24316953 DOI: 10.1097/DCR.0000000000000008]

44 **Buchs NC**, Nicholson GA, Yeung T, Mortensen NJ, Cunningham C, Jones OM, Guy R, Hompes R. Transanal rectal resection: an initial experience of 20 cases. *Colorectal Dis* 2015; in press

45 **Nagtegaal ID**, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH; Cooperative Clinical Investigators of the Dutch Colorectal Cancer G. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol* 2002; **20**: 1729-1734 [PMID: 11919228]

46 **Denost Q**, Adam JP, Rullier A, Buscail E, Laurent C, Rullier E. Perineal transanal approach: a new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. *Ann Surg* 2014; **260**: 993-999 [PMID: 24950270 DOI: 10.1097/SLA.0000000000000766]

47 **Gomez Ruiz M**, Martin Parra I, Calleja Iglesias A, Stein H, Sprinkle S, Manuel Palazuelos C, Alonso Martin J, Cagigas Fernandez C, Castillo Diego J, Gomez Fleitas M. Preclinical cadaveric study of transanal robotic proctectomy with total mesorectal excision combined with laparoscopic assistance. *Int J Med Robot* 2015; **11**: 188-193 [PMID: 24574007 DOI: 10.1002/rcs.1581]

48 **Atallah S**, Martin-Perez B, Pinan J, Quinteros F, Schoonyoung H, Albert M, Larach S. Robotic transanal total mesorectal excision: a pilot study. *Tech Coloproctol* 2014; **18**: 1047-1053 [PMID: 24957360 DOI: 10.1007/s10151-014-1181-5]

49 **Atallah S**, Nassif G, Polavarapu H, deBeche-Adams T, Ouyang J, Albert M, Larach S. Robotic-assisted transanal surgery for total mesorectal excision (RATS-TME): a description of a novel surgical approach with video demonstration. *Tech Coloproctol* 2013; **17**: 441-447 [PMID: 23801366 DOI: 10.1007/s10151-013-1039-2]

50 **Gómez Ruiz M**, Parra IM, Palazuelos CM, Martín JA, Fernández CC, Diego JC, Fleitas MG. Robotic-assisted laparoscopic transanal total mesorectal excision for rectal cancer: a prospective pilot study. *Dis Colon Rectum* 2015; **58**: 145-153 [PMID: 25489707 DOI: 10.1097/DCR.0000000000000265]

51 **Huscher CG**, Bretagnol F, Ponzano C. Robotic-assisted transanal total mesorectal excision: the key against the Achilles' heel of rectal cancer? *Ann Surg* 2015; **261**: e120-e121 [PMID: 25844970 DOI: 10.1097/SLA.0000000000001089]

52 **Verheijen PM**, Consten EC, Broeders IA. Robotic transanal total mesorectal excision for rectal cancer: experience with a first case. *Int J Med Robot* 2014; **10**: 423-426 [PMID: 24807675 DOI: 10.1002/rcs.1594]

53 **Atallah S**, Martin-Perez B, Parra-Davila E, deBeche-Adams T, Nassif G, Albert M, Larach S. Robotic transanal surgery for local excision of rectal neoplasia, transanal total mesorectal excision, and repair of complex fistulae: clinical experience with the first 18 cases at a single institution. *Tech Coloproctol* 2015; **19**: 401-410 [PMID: 25708682 DOI: 10.1007/s10151-015-1283-8]

54 **Buchs NC**, Ostermann S, Hauser J, Roche B, Iselin CE, Morel P. Intestinal obstruction following use of laparoscopic barbed suture: a new complication with new material? *Minim Invasive Ther Allied Technol* 2012; **21**: 369-371 [PMID: 22145693 DOI: 10.3109/13645706.2011.638643]

55 **Adamsen S**, Hansen OH, Funch-Jensen P, Schulze S, Stage JG, Wara P. Bile duct injury during laparoscopic cholecystectomy: a prospective nationwide series. *J Am Coll Surg* 1997; **184**: 571-578 [PMID: 9179112]

56 **Velthuis S**, Veltcamp Helbach M, Tuynman JB, Le TN, Bonjer HJ, Sietses C. Intra-abdominal bacterial contamination in TAMIS total mesorectal excision for rectal carcinoma: a prospective study. *Surg Endosc* 2015; Epub ahead of print [PMID: 25669639 DOI: 10.1007/s00464-015-4089-x]

57 **Feliciotti F**, Guerrieri M, Paganini AM, De Sanctis A, Campagnacci R, Perretta S, D'Ambrosio G, Lezoche E. Long-term results of laparoscopic versus open resections for rectal cancer for 124 unselected patients. *Surg Endosc* 2003; **17**: 1530-1535 [PMID: 12874687 DOI: 10.1007/s00464-002-8874-y]

58 **Hompes R**, Ashraf SQ, Gosselink MP, van Dongen KW, Mortensen NJ, Lindsey I, Cunningham C. Evaluation of quality of life and function at 1 year after transanal endoscopic microsurgery. *Colorectal Dis* 2015; **17**: O54-O61 [PMID: 25476189 DOI: 10.1111/codi.12858]

59 **Andersson J**, Abis G, Gellerstedt M, Angenete E, Angerås U, Cuesta MA, Jess P, Rosenberg J, Bonjer HJ, Haglind E. Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). *Br J Surg* 2014; **101**: 1272-1279 [PMID: 24924798 DOI: 10.1002/bjs.9550]

60 **Jayne DG**, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. *Br J Surg* 2005; **92**: 1124-1132 [PMID: 15997446 DOI: 10.1002/bjs.4989]

61 **Bislenghi G**, Wolthuis AM, de Buck van Overstraeten A, D'Hoore A. AirSeal system insufflator to maintain a stable pneumorectum during TAMIS. *Tech Coloproctol* 2015; **19**: 43-45 [PMID: 25421704 DOI: 10.1007/s10151-014-1244-7]

62 **Atallah S**, Nassif G, Larach S. Stereotactic navigation for TAMIS-TME: opening the gateway to frameless, image-guided abdominal and pelvic surgery. *Surg Endosc* 2015; **29**: 207-211 [PMID: 24972925 DOI: 10.1007/s00464-014-3655-y]

63 **Buchs NC**, Hompes R. Stereotactic navigation and augmented reality for transanal total mesorectal excision? *Colorectal Dis* 2015; **17**: 825-827 [PMID: 26139308 DOI: 10.1111/codi.13058]

64 **Buchs NC**, Volonte F, Pugin F, Toso C, Fusaglia M, Gavaghan K, Majno PE, Peterhans M, Weber S, Morel P. Augmented environments for the targeting of hepatic lesions during image-guided robotic liver surgery. *J Surg Res* 2013; **184**: 825-831 [PMID: 23684617 DOI: 10.1016/j.jss.2013.04.032]

65 **Peterhans M**, Oliveira T, Banz V, Candinas D, Weber S. Computer-assisted liver surgery: clinical applications and technological trends. *Crit Rev Biomed Eng* 2012; **40**: 199-220 [PMID: 22694200]

66 **Buchs NC**. Training in robotic general surgery: the next challenge. *Adv Robot Autom* 2012; **1**: e104

**P-Reviewer:** Ierardi e **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Transanal total mesorectal excision and peri-operative outcomes (case series with *n* ≥ 5)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of patients** | **ORT** | **Conversion rate** | **Complications rate** | **LOS** | **Comment** |
| Marks *et al*[[25](#_ENREF_25)], 2010 | 79 | NA | 2.5% | 29.9% | 5 | TATA approach! |
| Tuech *et al*[[22](#_ENREF_22)], 2015 | 56 | 270 | 7.3% | 26% | 10 | - |
| Han *et al*[[39](#_ENREF_39)], 2013 | 34 | 151.6 | 0 | 6 leaks | 9 | 13 with low rectal tumors, 15 with upper rectal tumors and 6 with sigmoid tumors. |
| Rouanet *et al*[[21](#_ENREF_21)], 2013 | 30 | 304 | 7% | Intraop: 10%  Postop: 30% | 14 | Difficult patients (male, high BMI, CRM threatened…) |
| Muratore *et al*[[20](#_ENREF_20)], 2015 | 26 | 241 | NA | 26.9% | NA | - |
| Atallah *et al*[[17](#_ENREF_17)], 2014 | 20 | 243 | NA | 65% | 4.5 | - |
| Buchs *et al*[[44](#_ENREF_44)], 2015 | 20 | 315.3 | 15% | 30% | 7 | 3 benign cases |
| De Lacy *et al*[[18](#_ENREF_18)], 2013 | 20 | 234 | 0 | 20% | 6.5 | No readmission |
| Chouillard *et al*[[29](#_ENREF_29)], 2014 | 16 | 265 | 6.25% | 18.8% | 10.4% | - |
| Wolthuis *et al*[[43](#_ENREF_43)], 2014 | 14 | 148 | 18% | 42.9% | 8.8 | No readmission |
| Knol *et al*[[40](#_ENREF_40)], 2015 | 10 | 235 | 0 | 10% | 6 | - |
| Velthuis *et al*[[42](#_ENREF_42)], 2013 | 5 | 175 | 0 | 40% | NA | - |
| Sylla *et al*[[41](#_ENREF_41)], 2013 | 5 | 274.6 | 0 | 60% | 5.2 |  |

BMI: Body mass index in kg/m2; ORT: Operative time in minutes; LOS: Length of stay in days; NA: Not available.

**Table 2 Transanal total mesorectal excision and pathological outcomes (case series with *n* ≥ 5)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **TME quality** | **Positive CRM** | **Distal margins** | **LN** |
| Marks *et al*[[25](#_ENREF_25)] | NA | 6.3% | 1.9 cm | 11.4 |
| Tuech *et al*[[22](#_ENREF_22)] | 84% intact and 16% nearly intact | 5.4% | 1 cm | 12 |
| Han *et al*[[39](#_ENREF_39)] | NA | 0% | 2.43 | 12.9 |
| Rouanet *et al*[[21](#_ENREF_21)] | 100% good | 13.3% | 0.9 cm | 13 |
| Muratore *et al*[[20](#_ENREF_20)] | 88.5% complete | 0% | 1.9 cm | 10 |
| Atallah *et al*[[17](#_ENREF_17)] | 89.5% complete or nearly complete | 5% | 5% positive | 22.5 |
| Buchs *et al*[[44](#_ENREF_44)] | 94.1% intact and 5.9% nearly intact | 5.9% | 2.14 cm | 23.2 |
| De Lacy *et al*[[18](#_ENREF_18)] | 100% satisfactory | 0% | 2.6 cm | 15.9 |
| Chouillard *et al*[[29](#_ENREF_29)] | 100% intact | 0% | 3.6 cm | 21 |
| Wolthuis *et al*[[43](#_ENREF_43)] | NA | NA | NA | NA |
| Knol *et al*[[40](#_ENREF_40)] | 90% intact | 0% | 1.94 cm | 10.5 |
| Velthuis *et al*[[42](#_ENREF_42)] | 100% intact | 0% | 0 positive | 12 |
| Sylla *et al*[[41](#_ENREF_41)] | 100% intact | 0% | 0 positive | 33 |

TME: Total mesorectal excision; CRM: Circumferential resection margins; LN: Lymph nodes; NA: Not available.

**Table 3 Comparative studies and peri-operative outcomes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of patients** | **ORT** | **Conversion rate** | **Complications rate** | **LOS** | **Readmission** |
| Denost *et al*[[46](#_ENREF_46)], 2014 | 50 lap TME  50 Perineal TaTME1 | 263  240 | 10%  4% | 44%  32% | 8  7 | NR |
| Fernandez-Hevia *et al*[[19](#_ENREF_19)], 2015 | 37 lap TME  37 TaTME | 252  215 | 0  0 | 51%  32% | 9  6.8 | 22%  6% |
| Velthuis *et al*[[23](#_ENREF_23)], 2014 | 25 lap TME  25 TaTME | NR | NR | NR | NR | NR |

1perineal dissection. Lap: Laparoscopy; TaTME: Transanal total mesorectal excision; ORT: Operative time in minutes; LOS: Length of stay in days; NR: Not reported. No use of laparoscopic instruments.

**Table 4 Comparative studies and pathological outcomes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Group** | **TME quality** | **Positive CRM** | **Distal margins** | **LN** |
| Denost *et al*[[46](#_ENREF_46)] | Lap TME  Perineal TaTME1 | 62% complete  70% complete | 18%  4% | 1 cm  1 cm | 17  17 |
| Fernandez-Hevia *et al*[[19](#_ENREF_19)] | Lap TME  TaTME | 94.6% complete  91.9% complete | 0  0 | 1.7 cm  2.8 cm | 14.7  14.3 |
| Velthuis *et al*[[23](#_ENREF_23)] | Lap TME  TaTME | 72% complete  96% complete | 8%  4% | 2.5 cm  2.3 cm | 13  14 |

1perineal dissection. Lap: Laparoscopy; TaTME: Transanal total mesorectal excision; CRM: Circumferential resection margins; LN: Lymph nodes. No use of laparoscopic instruments.

**Table 5 Robotic transanal total mesorectal excision**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of patients** | **ORT** | **Complications** | **LOS** | **Comments** |
| Huscher *et al*[[51](#_ENREF_51)], 2015 | 7 | 165.7 | 1 rectal bleeding, requiring blood transfusion. | 4.8 | Negative margins, 6 complete and one nearly complete TME. |
| Gomez Ruiz *et al*[[50](#_ENREF_50)], 2015 | 5 | 398 | 1 anastomotic leak | 6 | Negative margins, complete TME |
| Atallah *et al*[[48](#_ENREF_48)], 2014 | 3 | 376 | Pulmonary embolism, stoma high output | 4.3 | All complete or nearly complete TME. Negative margins. |
| Atallah *et al*[[49](#_ENREF_49)], 2013 | 1 | 381 | 0 | 3 | Negative margins, nearly complete TME |
| Verheijen *et al*[[52](#_ENREF_52)], 2014 | 1 | 205 | 0 | 3 | Negative margins, complete TME |

ORT: Operative time in minutes; LOS: Length of stay in days.